Slide 1: Developing next generation therapies against mental disorders
Gabather Developing next generation therapies against mental disorders Update 28-06-2023
Slide 2: Disclaimer
Disclaimer • Certain statements made during the course of this presentation are forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the company, or i
Slide 3: Agenda
Agenda 1. Gabather background 2. GT-002 Study update 3. Next steps Gabather
Slide 4: The Management Team
The Management Team Dr Michael-Robin Witt Dr Christine Ryan Stefan Rehnmark CEO/Board Member COO CSO • Ph.D. in Neuropharmacology from the • PhD in Neuroscience from University of • PhD in Physiology from the Wenner-Gren Royal School of Pharmacy, Copenhagen Cambridge and MBA from Stockholm Institute
Slide 5: Gabather brings long-term value to a deprived market
Gabather brings long-term value to a deprived market Gabather addresses a Gabather develops the Gabather is far along on major societal issue – next generation small its journey, finishing mental health molecules for mental Phase 1-trials with health positive results Gabather
Slide 6: The solution: Gabather researches high-precision compounds to minimise side effects
The solution: Gabather researches high-precision compounds to minimise side effects and maximise benefit to patients • Gabather is one of few actors on the CNS market who are developing compounds affecting the GABAA receptor • Lead candidate GT-002 has recently shown positive preliminary results in
Slide 7: Gabather has passed several milestones on its journey
Gabather has passed several milestones on its journey Q2 2019 Q1-Q4 2023 Positive outcome Q4 2022 Selection of new clinical drug candidate from Phase 1a SAD Initiating Phase 1b proof-of- for further development study in humans concept EEG study in humans Preparations for clinical Phase 2 study in pa
Slide 8: Explaining the phases of clinical trials
Explaining the phases of clinical trials Phase 1 Phase 2 Phase 3 Phase 4 Conducted on Conducted on a small Conducted on a large Conducted after the healthy, voluntary group of patients to group of patients to approval of the drug test subjects to study study the study the effect of a and is done to
Slide 9: Key insights: Three successful Phase 1 studies
Key insights: Three successful Phase 1 studies • Orally available capsule • Well tolerated • Safe • Upscaling of clinical trial material is finalized • First product form has been developed Gabather
Slide 10: Deep-dive: EEG as biomarker for selecting a drug for mental disorders
Deep-dive: EEG as biomarker for selecting a drug for mental disorders rawEEG Delta 1–4Hz Theta 4–8Hz Alpha 8–12Hz Beta 12–30Hz Gamma 30–100+Hz Gabather
Slide 11: Deep-dive: EEG disturbances in disease - normal vs mental disorder
Deep-dive: EEG disturbances in disease - normal vs mental disorder Normal Mental Relative EEG Band Power in Health and disorder Disease Delta 8 1–4Hz 6 Theta 4–8Hz 4 Alpha 2 8–12Hz 0 Beta Delta Theta Alpha Beta Gamma 12–30Hz -2 -4 Gamma 30–100Hz Normal Disease Gabather
Slide 12: Deep-dive: Lock and key – finding the right drug for a specific mental disorder
Deep-dive: Lock and key – finding the right drug for a specific mental disorder EEG Brain Signals 5 4 • The EEG pattern of GTX 3 2 inversely fits with the 1 altered EEG pattern of 0 the specific psychiatric -1 disorder -2 -3 • The GTX Key is selected -4 -5 GTX Disease for the treatment of this Delta
Slide 13: Deep-dive: Lock and key – unlocks mental disorders
Deep-dive: Lock and key – unlocks mental disorders Normal Mental GTX The GTX key Disorder 3 Delta 2 1–4Hz 1 0 Theta -1 4–8Hz -2 GTX -3 Alpha -4 8–12Hz -5 Gamma Beta Alpha Theta Delta Beta • The GTX drug key restores disease brain EEG 12–30Hz activity to normal EEG activity and treats the Patient Gam
Slide 14: Ongoing GT-002 study update: status
Ongoing GT-002 study update : status ● Site vist on June 11th-13 th 2023 ○ In-depth review of the process , personnel and project management ○ Journals, data acquisition and analysis process review ● Collected data to indicate interesting results regarding modulation of neural networks ○ Reviewed da
Slide 15: Ongoing GT-002 study update: Conclusions and solutions
Ongoing GT-002 study update : Conclusions and solutions ● Competent scientific team working with the GT-002 trial ● EEG/fMRI studies generate the highest value data in CNS clinical studies ● New data acquisition schedule agreed June 2023 ● GT has the know-how, the process is time consuming and inclu
Slide 16: Gabather 2023: next steps
Gabather 2023: next steps ● Gabather is actively pursuing a strategy to enhance, sharpen and refine its expertise. ● Proposed plan is to expand the board of directors with two new members. ● Gabathers identified key subject experts are: ○ Åsa Kornfeld - more than 25 years of experience in; maximizin
Slide 17: Ongoing GT-002 study update: next steps, clinical indication expansion strategy
Ongoing GT-002 study update : next steps Clinical indication expansion strategy for GT-002 EEG fMRI Normal Mental Schizophrenia disorder Post-traumatic Autism stress disorder Delta 1–4Hz Theta Frontotemporal Amyotrophic EEG 4–8Hz Dementia Lateral fMRI Sclerosis (ALS) (FTD) Alpha 8–12Hz Beta Mild cog
Slide 18: Next steps: aiming to reach commercial partnerships
Next steps: aiming to reach commercial partnerships • For full clinical development and commercialisation of Gabather’s compound, partnerships are required • Most likely such partnerships will be made with established players on the market • The success of reaching partnerships is based on the resul
Slide 19: Thank you!
Gabatner Thank you ! AHG Offenburg -